Status:
COMPLETED
Role of FGF-23 as a Prognosis Biomarker in Intensive Care Patients
Lead Sponsor:
University of Chile
Conditions:
Sepsis
Acute Kidney Injury
Eligibility:
All Genders
15-89 years
Brief Summary
The purpose of the study is to evaluate the potential role of plasmatic Fibroblast Growth Factor 23 (FGF-23) as a prognosis predictor of clinical outcomes in Critical Care patients.
Detailed Description
Observational study of patients admitted in the Critical Care Unit (CCU) of University of Chile Clinical Hospital, admitted with diagnosis of severe sepsis/septic shock. Exclusion criteria: Pregnancy...
Eligibility Criteria
Inclusion
- Admission in Critical Care Unit
- Sepsis
Exclusion
- Pregnancy
- Organ transplantation
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT01801501
Start Date
January 1 2012
End Date
December 1 2018
Last Update
May 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chile Clinical Hospital
Santiago, RM, Chile, 8380456